AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27165711 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 90 mg/day for 10 days followed by 60 mg/day
Number of subjects: 85
Study 27165711 — intervention group
Group type: COMPARATOR
Intervention: Parenteral anticoagulation bridging to warfarin for 3 months
Number of subjects: 85
Study 27165711 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 85
Study 27165711 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 85
Study 27165711 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 26280592 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment condition (AT; n = 31)
Number of subjects: 62
Study 26280592 — intervention group
Group type: COMPARATOR
Intervention: Control treatment condition (CT; n = 31)
Number of subjects: 62
Study 26280592 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (AT and CT)
Number of subjects: 62
Study 23590301 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMC gene expression profiles in smokers with COPD
Number of subjects: 136
Study 23590301 — intervention group
Group type: EXPERIMENTAL
Intervention: Candidate genes validated in independent cohort
Number of subjects: 136
Study 23590301 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma metabolomics
Number of subjects: 136
Study 23590301 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathways analysis
Number of subjects: 136
Study 20459731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischaemic preconditioning (IPC)
Number of subjects: 20
Study 20459731 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 20
Study 19808428 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 8828
Study 19808428 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 8828
Study 19808428 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HR on in-treatment ECGs
Number of subjects: 8828
Study 19808428 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistence or development of HR ≥84
Number of subjects: 8828
Study 19808428 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher in-treatment HR
Number of subjects: 8828
Study 16650165 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine treatment for 4 weeks
Number of subjects: 10
Study 16650165 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 10
Study 12118963 — intervention group
Group type: EXPERIMENTAL
Intervention: TPI (Thrombolytic Predictive Instrument)
Number of subjects: 1197
Study 12118963 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1197
Study 10402447 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 550
Study 10402447 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 550
Study 7778523 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication-games intervention with seven interactive elements drawn from the parent-child interaction literature
Number of subjects: 20
Study 7778523 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 2080486 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 tablet of althiazide (15 mg) and spironolactone (25 mg)
Number of subjects: 12
Study 2080486 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 tablets of althiazide (15 mg) and spironolactone (25 mg)
Number of subjects: 12
Study 492804 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 0
Study 492804 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate 1.0 mg/kg
Number of subjects: 0
Study 492804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31980138 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender disparity perceptions among surgeons
Number of subjects: 36
Study 31980138 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns with gaps in mentoring
Number of subjects: 36
Study 31980138 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficulties finding role models
Number of subjects: 36
Study 31980138 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacrifices for professional advancement
Number of subjects: 36
Study 31980138 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived biases against female surgeons
Number of subjects: 36
Study 29565195 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-mediated labour induction
Number of subjects: 1971
Study 29565195 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) agents - propess
Number of subjects: 1971
Study 29565195 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) agents - prostin
Number of subjects: 1971
Study 29565195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propess and prostin
Number of subjects: 1971
Study 29565195 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple combinations of induction modalities
Number of subjects: 1971
Study 27581328 — intervention group
Group type: EXPERIMENTAL
Intervention: Biweekly phone-based group counseling
Number of subjects: 0
Study 27581328 — intervention group
Group type: COMPARATOR
Intervention: Mailed newsletters
Number of subjects: 0
Study 23470116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for anxiety
Number of subjects: 227
Study 23470116 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 227
Study 23496893 — intervention group
Group type: EXPERIMENTAL
Intervention: Online program including a physical activity lesson
Number of subjects: 512
Study 20357375 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (4-week treatment)
Number of subjects: 32
Study 20357375 — intervention group
Group type: COMPARATOR
Intervention: No additional treatment (Control)
Number of subjects: 32
Study 18093679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheneau brace full-time (23/24 hours)
Number of subjects: 108
Study 18093679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheneau brace part-time (night only)
Number of subjects: 108
Study 18093679 — intervention group
Group type: COMPARATOR
Intervention: No brace (control group)
Number of subjects: 108
Study 18093679 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheneau brace (both full-time and part-time)
Number of subjects: 108
Study 16155380 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone in combination with inhaled nitric oxide (iNO)
Number of subjects: 4
Study 16155380 — intervention group
Group type: COMPARATOR
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 4
Study 12862328 — intervention group
Group type: EXPERIMENTAL
Intervention: Malarone (atovaquone 250 mg/proguanil 100 mg)
Number of subjects: 28
Study 12862328 — intervention group
Group type: EXPERIMENTAL
Intervention: Primaquine (30 mg of base)
Number of subjects: 28
Study 12862328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 12862328 — intervention group
Group type: EXPERIMENTAL
Intervention: Malarone and Primaquine
Number of subjects: 28
Study 10979164 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment on postoperative days 2 through 5
Number of subjects: 76
Study 9117755 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% Amlexanox paste
Number of subjects: 991
Study 7686120 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b
Number of subjects: 23
Study 7686120 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 23
Study 3555355 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocolloid dressings (HCDs)
Number of subjects: 52
Study 3555355 — intervention group
Group type: COMPARATOR
Intervention: Dakin's solution (chloramine‐T)‐soaked wet‐to‐dry dressings
Number of subjects: 52
Study 31618466 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) with a parent
Number of subjects: 55
Study 31618466 — intervention group
Group type: COMPARATOR
Intervention: Care on a resuscitaire and later in an incubator or bed
Number of subjects: 55
Study 28811354 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg QD
Number of subjects: 201
Study 28811354 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg QD
Number of subjects: 201
Study 28811354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 201
Study 27180621 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified substrate ablation procedure with scar dechanneling as the first step (group 1)
Number of subjects: 48
Study 27180621 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure with VT induction, mapping, and ablation followed by scar dechanneling (group 2)
Number of subjects: 48
Study 27180621 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (after substrate ablation)
Number of subjects: 48
Study 27180621 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (after substrate ablation)
Number of subjects: 48
Study 27180621 — intervention group
Group type: EXPERIMENTAL
Intervention: End-procedure success (after residual inducible VT ablation)
Number of subjects: 48
Study 27180621 — intervention group
Group type: EXPERIMENTAL
Intervention: VT recurrence rate
Number of subjects: 48
Study 25525672 — intervention group
Group type: COMPARATOR
Intervention: WebChoice
Number of subjects: 167
Study 25525672 — intervention group
Group type: COMPARATOR
Intervention: IPPC
Number of subjects: 167
Study 25525672 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 167
Study 22076246 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dexamphetamine
Number of subjects: 18
Study 22076246 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 18
Study 22076246 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg dexamphetamine + 0.8 g/kg alcohol
Number of subjects: 18
Study 22076246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 20587954 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation technique
Number of subjects: 40
Study 20587954 — intervention group
Group type: EXPERIMENTAL
Intervention: BeeFill system
Number of subjects: 40
Study 20587954 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (lateral condensation technique)
Number of subjects: 40
Study 20587954 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (not root‐filled)
Number of subjects: 40
Study 18767576 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zhongji (CV 3)
Number of subjects: 276
Study 18767576 — intervention group
Group type: COMPARATOR
Intervention: Medication group with oral administration of Qianliekang tablets
Number of subjects: 276
Study 15929961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients
Number of subjects: 104
Study 15929961 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 104
Study 15929961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients with severe lung disease (FEV(1) <40% predicted)
Number of subjects: 104
Study 15929961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystic fibrosis patients with mild or moderate pulmonary disease
Number of subjects: 104
Study 12351296 — intervention group
Group type: EXPERIMENTAL
Intervention: Median approach transsacral epidural block (S2-3 group)
Number of subjects: 30
Study 12351296 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal approach transsacral epidural block (caudal group)
Number of subjects: 30
Study 9891521 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin and ifosfamide (11 patients)
Number of subjects: 14
Study 9891521 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with carboplatin and paclitaxel (3 patients)
Number of subjects: 14
Study 9891521 — intervention group
Group type: COMPARATOR
Intervention: No neoadjuvant chemotherapy (6 patients with no change)
Number of subjects: 14
Study 7731896 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin administration
Number of subjects: 30
Study 7731896 — intervention group
Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 30
Study 7731896 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialyzed patients with end stage renal failure
Number of subjects: 30
Study 2691483 — intervention group
Group type: EXPERIMENTAL
Intervention: Single pre-operative dose of 2.2 g amoxycillin/clavulanate
Number of subjects: 467
Study 2691483 — intervention group
Group type: COMPARATOR
Intervention: Combination of 1.5 g cefuroxime plus 0.5 g metronidazole
Number of subjects: 467
Study 4932797 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim-sulphamethoxazole
Number of subjects: 0
Study 4932797 — intervention group
Group type: COMPARATOR
Intervention: Sulphamethoxazole
Number of subjects: 0
Study 4932797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study 371733 — intervention group
Group type: EXPERIMENTAL
Intervention: Low osmolality contrast medium (sodium‐methyl‐glucamine‐ioxaglate)
Number of subjects: 12
Study 371733 — intervention group
Group type: COMPARATOR
Intervention: Conventional compound (methylglucamine‐ioxitalamate)
Number of subjects: 12
Study 31371432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 200 mg
Number of subjects: 1575
Study 31371432 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotagliflozin 400 mg
Number of subjects: 1575
Study 31371432 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1575
Study 28606661 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training using Xbox Kinect plus conventional physical therapy (30 minutes each)
Number of subjects: 20
Study 28606661 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy only (30 minutes)
Number of subjects: 20
Study 28606661 — intervention group
Group type: EXPERIMENTAL
Intervention: VR training using Xbox Kinect plus conventional physical therapy
Number of subjects: 20
Study 25848859 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 26
Study 25848859 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 26
Study 23585422 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol hand rub
Number of subjects: 35
Study 23585422 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine hand scrub
Number of subjects: 35
Study 23585422 — intervention group
Group type: COMPARATOR
Intervention: Plain soap hand wash
Number of subjects: 35
Study 21418260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase delayed-release capsules (Creon) at a mean dose of 186960±74640 lipase units/day
Number of subjects: 51
Study 21418260 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancrelipase delayed-release capsules (Creon)
Number of subjects: 51
Study 19238545 — intervention group
Group type: EXPERIMENTAL
Intervention: LIFT intervention
Number of subjects: 351
Study 17365975 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis followed by immediate coronary angiography and intervention
Number of subjects: 266
Study 17365975 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis followed by conservative management
Number of subjects: 266
Study 15084794 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg daily) plus cognitive training (images of everyday life and reminiscent music, 3 sessions per week for 12 months)
Number of subjects: 86
Study 15084794 — intervention group
Group type: COMPARATOR
Intervention: Donepezil (10 mg daily)
Number of subjects: 86
Study 11284571 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment using a Herbert bone screw
Number of subjects: 61
Study 11284571 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment using a cast
Number of subjects: 61
Study 11284571 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 61
Study 9526933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's acetate (AR)
Number of subjects: 60
Study 9526933 — intervention group
Group type: COMPARATOR
Intervention: Ringer's lactate (LR)
Number of subjects: 60
Study 7983221 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMD/R)
Number of subjects: 30
Study 7983221 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization with Music (EMD/M)
Number of subjects: 30
Study 7983221 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 2519941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gram of nafcillin in 10 mL of saline as an intravenous (IV) bolus
Number of subjects: 45
Study 2519941 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 gram of nafcillin in 50 mL of saline as a slow IV infusion over 15 minutes
Number of subjects: 45
Study 2519941 — intervention group
Group type: COMPARATOR
Intervention: No nafcillin administration (Control group)
Number of subjects: 45
Study 5763961 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine given with atropine
Number of subjects: 46
Study 5763961 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine given after atropine
Number of subjects: 46
Study 5763961 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine given before or with neostigmine
Number of subjects: 46
Study 31619654 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-high hydrostatic pressurized brown rice (UHHPBR) intake group (n=20) consuming 100 g of UHHPBR and 100 g of white rice (WR) per day for 12 months
Number of subjects: 40
Study 31619654 — intervention group
Group type: COMPARATOR
Intervention: White rice (WR) intake group (n=20) consuming 200 g of WR per day for 12 months
Number of subjects: 40
Study 28301687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG; n=20) applied at the point of greatest pain, three times per week for a total of six sessions.
Number of subjects: 40
Study 28301687 — intervention group
Group type: COMPARATOR
Intervention: Sham ozone therapy (PG; n=20) applied at the point of greatest pain, three times per week for a total of six sessions.
Number of subjects: 40
Study 28301687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) at 3 months (T2) for temporal muscle PPT.
Number of subjects: 40
Study 28301687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) at 3 months (T2) for masseter muscle PPT.
Number of subjects: 40
Study 28301687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) at 3 months (T2) for lateral pole PPT.
Number of subjects: 40
Study 28301687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) for right lateral excursion at 3 months (T2).
Number of subjects: 40
Study 28301687 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone therapy (OG) for overall VAS scores from baseline to 3 months.
Number of subjects: 40
Study 25894894 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-38893777 (doses: 5, 15, 45, 125, 250, or 500 mg)
Number of subjects: 80
Study 25894894 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-38893777 (250 mg in fasting state and 250 mg, 375 mg, or 500 mg in high-fat fed state)
Number of subjects: 80
Study 25894894 — intervention group
Group type: EXPERIMENTAL
Intervention: JNJ-38893777
Number of subjects: 80
Study 25894894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23562359 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanwell/Ethanzyme (EE) regimen enriched with omega‐3 fatty acids, micronutrients, and probiotics
Number of subjects: 68
Study 23562359 — intervention group
Group type: COMPARATOR
Intervention: Isocal (control)
Number of subjects: 68
Study 21429223 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intradermal sterile water injection (SWI) technique
Number of subjects: 319
Study 21429223 — intervention group
Group type: COMPARATOR
Intervention: Four intradermal sterile water injection (SWI) technique
Number of subjects: 319
Study 19752426 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic atrophy (GA) area measurement using digitized fundus photographs
Number of subjects: 181
Study 19752426 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of central GA
Number of subjects: 181
Study 19752426 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual acuity measurement
Number of subjects: 181
Study 16406154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cingulate gyrus atrophy rates in AD
Number of subjects: 38
Study 16406154 — intervention group
Group type: EXPERIMENTAL
Intervention: Cingulate gyrus atrophy rates in FTLD
Number of subjects: 38
Study 16406154 — intervention group
Group type: COMPARATOR
Intervention: Cingulate gyrus atrophy rates in controls
Number of subjects: 38
Study 16406154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal atrophy rates in AD
Number of subjects: 38
Study 16406154 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal atrophy rates in FTLD
Number of subjects: 38
Study 16406154 — intervention group
Group type: COMPARATOR
Intervention: Hippocampal atrophy rates in controls
Number of subjects: 38
Study 15220018 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride + Pioglitazone (G + P)
Number of subjects: 91
Study 15220018 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride + Rosiglitazone (G + R)
Number of subjects: 91
Study 12456607 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 3052
Study 12456607 — intervention group
Group type: COMPARATOR
Intervention: 25 mg mifepristone
Number of subjects: 3052
Study 9640189 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost monotherapy (50 micrograms/ml)
Number of subjects: 22
Study 9640189 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipivefrin monotherapy (1 mg/ml)
Number of subjects: 22
Study 9640189 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of latanoprost and dipivefrin
Number of subjects: 22
Study 9640189 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost and dipivefrin (combined)
Number of subjects: 22
Study 7979527 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg of cromoglycate three times a day by wet nebulisation (n = 16)
Number of subjects: 31
Study 7979527 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline as placebo three times a day by wet nebulisation (n = 15)
Number of subjects: 31